MilestoneAug 17, 2026, 12:17 UTC

OneDigital takes new $1.9M stake in Axsome Therapeutics

What's the deal? OneDigital Investment Advisors LLC bought a new position in Axsome Therapeutics (NASDAQ:AXSM) in the second quarter, according to its latest Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,787 shares, valued at about $1,906,000.

Who else is buying? Several institutional investors adjusted their AXSM holdings in recent quarters. Price T Rowe Associates raised its stake 45.5% to 1,509,870 shares worth $275,763,000; Wellington Management lifted its position 84.1% to 1,334,560 shares valued at $162,082,000.

Invesco, Geode Capital Management, and State Street also added shares. Institutional investors and hedge funds now own 81.49% of the stock.

What do analysts say? AXSM holds a consensus "Moderate Buy" rating and a $267.60 average price target, per MarketBeat. Two analysts rate it strong buy, 16 buy, two hold, and two sell.

Mixed signals Recent notes diverged. Royal Bank of Canada cut its target from $304 to $297 on August 11 while keeping an "outperform" rating, and HC Wainwright reiterated a "buy" with a $290 target on July 15. Zacks Research went the other way, downgrading the stock from "hold" to "strong sell" on July 20.

Insider moves Directors sold shares in June. Mark Coleman sold 6,000 shares at an average $230.30, cutting his position 14.58%, while Susan Mahony sold 300 shares at an average $237.21.

The signal: A small new stake from OneDigital adds to heavy institutional interest in Axsome, though split analyst views and insider selling point to caution around the biopharma name.